CHO cell line development using CRISPR site-specific integration and UCOE anti-silencing technology. Consistently achieving 3–5 g/L, stable 60+ generations, GMP-ready in 10–16 weeks.
Stable cell line development is the process of engineering mammalian cells — most commonly Chinese Hamster Ovary (CHO) cells — to permanently express a recombinant antibody or protein at high, consistent levels. Unlike transient expression, where gene expression is temporary and varies between preparations, stable cell lines integrate the transgene into the host genome and produce the same protein at reproducible levels batch after batch.
For biopharmaceutical manufacturing, stable cell line development is non-negotiable. Regulatory agencies including the FDA and EMA require thoroughly characterized, stable master cell banks as the starting material for GMP production. The quality, consistency, and long-term stability of the cell line directly determines the commercial viability of a biologic drug.
The key challenge in traditional stable cell line development is clonal variability. When a transgene integrates randomly into the genome, different clones show widely varying expression levels and stability profiles. Identifying a manufacturing-suitable clone requires screening hundreds to thousands of candidates — a time-consuming and expensive bottleneck. AntibodyLLM's CRISPR-based platform eliminates this bottleneck by directing integration to a single, optimal genomic location.
CRISPR-Cas9 directs insertion of the transgene to a single, pre-validated "hot spot" in the CHO genome — a locus confirmed to support high, stable expression. Every clone receives the gene at the same chromosomal location, eliminating positional effects.
UCOE (Ubiquitous Chromatin Opening Element) is incorporated into the gene construct to maintain open chromatin around the transgene, preventing epigenetic methylation and gene silencing during long-term culture.
Codon optimization, signal peptide selection, UCOE element integration, and GS selection cassette assembly. Gene synthesis and sequence verification.
Rapid transient expression in CHO to confirm protein expression, secretion, and basic product quality before committing to stable cell line development.
CRISPR-Cas9 electroporation, GS selection, and stable pool generation. Pool productivity assessment confirms integration success before single-cell cloning.
FACS or limiting dilution single-cell cloning. High-throughput productivity screening in 96-well plates with ELISA titer measurement. Top clones promoted for scale-up characterization.
Extended culture stability study (60 generations). Preparation of master cell bank (MCB) and working cell bank (WCB). Full characterization package including adventitious agent testing.
IgG1, IgG2, IgG4 subtypes. Full-length and fragment formats (Fab, scFv, VHH).
Knob-into-hole, CrossMab, DART, and tandem scFv formats. Chain pairing engineered by AI design.
Cytokine-Fc, receptor-Fc, and peptide-Fc fusions with IgG1 or IgG4 backbones.
Growth factors, enzymes, viral antigens, and other therapeutic proteins requiring human-compatible glycosylation.
CHO-K1 (GS selection), CHO-DG44 (DHFR selection). HEK293 available for specific applications.
From research-scale shake flask (100 mL) to GMP bioreactor (up to 2,000 L) via our monoclonal antibody production service.
Transient expression is temporary — the plasmid remains episomal and is diluted out over successive cell divisions, typically lasting 1–2 weeks. It is used for rapid protein production and feasibility testing. Stable cell line development integrates the transgene into the genome permanently, enabling consistent, long-term production suitable for clinical manufacturing and commercial supply.
CRISPR site-specific integration delivers every clone with the transgene at the same genomic locus, so expression levels are predictable. Traditional random integration requires screening hundreds of clones to find the rare high-expressors. CRISPR integration reduces the clonal screening burden by 60%, compressing development timelines from 6+ months to 10–16 weeks.
Gene silencing occurs when epigenetic methylation condenses the chromatin around an integrated transgene, progressively shutting down transcription. This is a major cause of productivity loss in CHO cell lines during long-term culture. UCOE elements derived from human housekeeping gene promoters maintain open chromatin conformation around the transgene, preventing methylation and ensuring stable expression for 60+ generations.
Full documentation includes: vector map and sequence file, integration confirmation (PCR/NGS), cell line characterization report (morphology, growth kinetics, viability), productivity data (titer across development), long-term stability data (60 generations), MCB/WCB certificates, and adventitious agent testing reports (mycoplasma, sterility, viral testing).
Yes. AntibodyLLM has specialized expertise in bispecific antibody cell line development. Our CRISPR integration system supports dual-transgene constructs, and our AI platform designs the chain pairing strategy to minimize mispairing. Supported bispecific formats include knob-into-hole IgG, CrossMab, and tandem scFv fusions.
Yes. Every cell line development project is executed with GMP manufacturing in mind. The cell banking and characterization process follows ICH Q5B/Q5D guidelines. The master cell bank generated is suitable as the starting material for GMP production and supports IND-enabling studies, Phase I–III clinical trials, and BLA/NDA regulatory submissions.
Share your gene construct or antibody sequence and we'll provide a development timeline and quote within 48 hours.
Get a Quote